Literature DB >> 25661795

Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.

Justine L Kuiper1, Merle I Ronden1, Annemarie Becker1, Daniëlle A M Heideman2, Peter van Hengel3, Bauke Ylstra2, Erik Thunnissen2, Egbert F Smit4.   

Abstract

Entities:  

Keywords:  CANCER; LUNG CANCER; ONCOLOGY

Mesh：

Substances：

Year:  2015        PMID： 25661795     DOI： 10.1136/jclinpath-2015-202866

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  13 in total

Review 1.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

2.  Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.

Authors:  Hyung Kyu Park; Youjeong Seo; Yoon-La Choi; Myung-Ju Ahn; Joungho Han
Journal:  J Pathol Transl Med       Date:  2017-04-04

3.  EGFR mutations subset in Chinese lung squamous cell carcinoma patients.

Authors:  Ying Sun; Xin Yin; Miao-Miao Wen; Jiao Zhang; Xue-Jiao Wang; Jing-Hua Xia; Yan-Ning Zhang; Zhi-Pei Zhang; Xiao-Fei Li
Journal:  Mol Med Rep       Date:  2018-04-05       Impact factor: 2.952

Review 4.  Pathological transition as the arising mechanism for drug resistance in lung cancer.

Authors:  Yueqing Chen; Waiying Yvonne Tang; Xinyuan Tong; Hongbin Ji
Journal:  Cancer Commun (Lond)       Date:  2019-10-01

5.  Transformation from Small Cell to Squamous Cell Carcinoma in a Thymic Carcinoma Patient with a Durable Response to Anlotinib: A Case Report.

Authors:  Wenru Qin; Bing Zou; Xinyu Fan; Bingjie Fan; Shijiang Wang; Linlin Wang
Journal:  Cancer Manag Res       Date:  2022-04-29       Impact factor: 3.989

Review 6.  Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.

Authors:  Fiorella Calabrese; Federica Pezzuto; Francesca Lunardi; Francesco Fortarezza; Sofia-Eleni Tzorakoleftheraki; Maria Vittoria Resi; Mariaenrica Tiné; Giulia Pasello; Paul Hofman
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

Review 7.  T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review.

Authors:  Yusaku Kusaba; Yuichiro Takeda; Sakurako Abe; Akinari Tsukada; Go Naka
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 8.  Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.

Authors:  Ravi Salgia
Journal:  Expert Rev Mol Diagn       Date:  2016-05-26       Impact factor: 5.225

Review 9.  Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.

Authors:  Yingjiao Xue; Shenda Hou; Hongbin Ji; Xiangkun Han
Journal:  Protein Cell       Date:  2016-10-18       Impact factor: 14.870

10.  Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report.

Authors:  Yufeng Yao; Zhouyu Zhu; Yimin Wu; Ying Chai
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.